- Laureate To Manufacture Alopexx's Product Candidate -
PRINCETON, N.J., April 10, 2008 /PRNewswire/ -- Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Alopexx Pharmaceuticals, LLC. According to the agreement, Laureate will produce Alopexx's mAb F598 antibody under cGMP conditions. This antibody is planned for use in clinical trials, and later for commercial production for the treatment and prevention of Staphylococcus aureus infections. Terms of the manufacturing agreement were not disclosed.
"We are pleased that Alopexx chose Laureate Pharma as their manufacturing partner," said Robert J. Broeze, Ph. D., President & CEO of Laureate. "We will closely collaborate with the Alopexx team and help them drive their product from development into the clinic."
"Laureate Pharma has a track record of demonstrated expertise in biopharmaceutical manufacturing, including capabilities in both clinical and commercial-grade materials," said Dr. Daniel Vlock, President and CEO of Alopexx. "We look forward to our partnership with Laureate and advancing our antibody therapeutics program into the clinic."
About Laureate Pharma, Inc.
Laureate Pharma is a full-service biopharmaceutical development and
protein production company located in Princeton, New Jersey. Laureate
Pharma offers superior bioprocessing services that accelerate new products
from development through production. Laureate provides a wide range of
specialized services from process design and development to full-scale cGMP
production, purification, aseptic filling, testing, validation, analytical
services, and regulatory support. Laureate is focused on two active
segments of the biopha
|SOURCE Laureate Pharma, Inc.|
Copyright©2008 PR Newswire.
All rights reserved